China wants 5 innovative drugs with US$1 billion returns by 2030. Which might they be?

The increasing global appeal of Chinese firms’ novel therapies has propelled the country’s rise as a biomedical powerhouse, but China has yet to produce a drug to rival all-time best-selling Western blockbusters in sales. Beijing has set ambitious new five-year targets to boost its global presence, including at leas…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.